Biocon Biologics Enhances Oncology Portfolio: New Biosimilars and Integrated Strategy Announced

Biocon Biologics to Expand Oncology Biosimilar Portfolio, Outline Strategic Integration at 2026 J.P. Morgan Healthcare Conference

Biocon Biologics Ltd. (BBL), a global biosimilars company and subsidiary of Biocon Ltd., announced plans to introduce three new oncology biosimilars—Trastuzumab/Hyaluronidase (Herceptin® SC/Herceptin HYLECTA™), Nivolumab (Opdivo®), and Pembrolizumab (Keytruda®)—at the 44th Annual J.P. Morgan Healthcare Conference. The expansion strengthens BBL’s oncology portfolio, enabling broader access to affordable cancer therapies.

The company will also present its strategic plan to integrate as a wholly owned subsidiary of Biocon Ltd., combining global commercial infrastructure to streamline operations and reinforce leadership in diabetes, oncology, and immunology. The integration is expected to be completed by March 31, 2026, positioning Biocon uniquely as a provider of both biosimilar insulins and GLP-1 peptide generics.

Shreehas Tambe, CEO & Managing Director of Biocon Biologics, emphasized,

“Our integration with Biocon Ltd. will enhance our ability to deliver biosimilars and generics at global scale, expanding access to high-quality, affordable medicines across diabetes, oncology, and immunology. Guided by science-led R&D, we are advancing a strong pipeline with 17 oncology assets to meet diverse patient needs worldwide.”

The Biocon Biologics presentation will be webcast live on January 15, 2026, with a replay available on the company’s investor relations website. Tambe will also participate in a fireside chat at ENDPOINTS at JPM26 on January 13, 2026, discussing the promise of biosimilars.